Profile data is unavailable for this security.
About the company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
- Revenue in EUR (TTM)305.28m
- Net income in EUR321.90k
- Incorporated1988
- Employees426.00
- LocationPharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
- Phone+31 715247400
- Fax+31 715247445
- Websitehttps://www.pharming.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Consumer Healthcare India Ltd | 75.96m | 20.27m | 919.38m | 583.00 | 45.35 | -- | 43.49 | 12.10 | 94.62 | 94.62 | 354.49 | -- | -- | -- | -- | 14,003,430.00 | -- | -- | -- | -- | 75.05 | -- | 26.69 | -- | -- | 143.16 | -- | -- | 30.45 | -- | 9.76 | -- | -- | -- |
| Wuhan Keqian Biology Co Ltd | 123.70m | 56.05m | 922.65m | 924.00 | 16.57 | 1.81 | -- | 7.46 | 0.9796 | 0.9796 | 2.16 | 8.95 | 0.2209 | 2.86 | 3.23 | 1,097,706.00 | 9.97 | 11.71 | 11.17 | 13.56 | 65.26 | 73.57 | 45.16 | 44.51 | 5.02 | -- | 0.0017 | 32.23 | -11.48 | 13.17 | -3.43 | 9.52 | -4.93 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 194.64m | -40.57m | 933.02m | 2.35k | -- | 1.05 | -- | 4.79 | -0.3545 | -0.3545 | 1.70 | 7.75 | 0.1303 | 0.6358 | 0.4977 | 679,399.90 | -2.74 | 3.29 | -3.80 | 4.46 | 44.16 | 37.24 | -21.03 | 10.59 | 1.33 | -1.45 | 0.3114 | 24.43 | -13.90 | -3.87 | -7.30 | 1.41 | 1.13 | -7.12 |
| Pharming Group NV | 305.28m | 321.90k | 933.72m | 426.00 | 388.15 | 4.16 | 70.22 | 3.06 | 0.0034 | 0.0034 | 0.481 | 0.3201 | 0.8057 | 0.5655 | 7.89 | 716,613.70 | 0.0156 | 2.22 | 0.0191 | 2.68 | 89.90 | 89.40 | 0.0193 | 3.88 | 2.39 | 3.14 | 0.331 | -- | 21.15 | 9.46 | -12.26 | -- | -49.98 | -- |
| Mega Lifesciences PCL | 383.59m | 53.56m | 934.23m | 5.31k | 17.45 | 3.56 | 14.76 | 2.44 | 2.26 | 2.26 | 16.21 | 11.11 | 1.00 | 2.17 | 4.65 | 2,661,453.00 | 14.01 | 14.52 | 19.99 | 22.35 | 52.23 | 44.65 | 13.96 | 13.04 | 1.62 | 4.75 | 0.0599 | 50.84 | -2.15 | 6.63 | 0.994 | 12.07 | -13.81 | 17.32 |
| CStone Pharmaceuticals | 24.72m | -46.04m | 941.96m | 93.00 | -- | 22.64 | -- | 38.10 | -0.3277 | -0.3277 | 0.177 | 0.2615 | 0.1487 | 1.38 | 1.68 | 1,698,809.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| Cisen Pharmaceutical Co Ltd | 434.55m | 60.10m | 946.98m | 3.30k | 15.81 | 1.26 | -- | 2.18 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| SSY Group Ltd | 493.89m | 71.03m | 947.00m | 5.70k | 13.59 | 1.23 | 7.82 | 1.92 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| Xeris Biopharma Holdings Inc | 224.24m | -13.18m | 953.46m | 394.00 | -- | -- | -- | 4.25 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| China Animal Husbandry Industry Co., Ltd | 766.04m | 26.15m | 955.21m | 4.30k | 36.52 | 1.37 | -- | 1.25 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
| Polypeptide Group AG | 370.37m | -34.70m | 959.51m | 1.37k | -- | 2.89 | -- | 2.59 | -0.9494 | -0.9494 | 10.09 | 9.14 | 0.5153 | 2.06 | 6.35 | 261,379.80 | -4.83 | 0.555 | -6.57 | 0.7099 | 11.63 | 19.25 | -9.37 | 1.05 | 0.8234 | -0.1909 | 0.2517 | 62.37 | 4.28 | 10.70 | 61.97 | -- | 34.57 | -- |
Data as of Feb 16 2026. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR
11.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Acadian Asset Management LLCas of 09 Jan 2026 | 21.46m | 3.06% |
| Norges Bank Investment Managementas of 06 Feb 2026 | 20.74m | 2.96% |
| BlackRock Fund Advisorsas of 04 Feb 2026 | 15.78m | 2.25% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 7.89m | 1.13% |
| DWS Investment GmbHas of 06 Feb 2026 | 3.61m | 0.51% |
| Deka Investment GmbHas of 05 Feb 2026 | 2.96m | 0.42% |
| Lazard Asset Management LLCas of 31 Jan 2026 | 2.80m | 0.40% |
| Parametric SASas of 14 Jan 2025 | 2.79m | 0.40% |
| Nordea Investment Management ABas of 31 Dec 2025 | 2.74m | 0.39% |
| BlackRock Advisors (UK) Ltd.as of 04 Feb 2026 | 2.64m | 0.38% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
